Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)
Conditions
Interventions
None listed
Sponsors
The Japanese Respiratory Society
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In the systematic review and meta-analysis assessing the differences in outcomes between high- and low-risk patients, studies which met all three of the following inclusion criteria are considered eligible: (1) prospective studies in patients with HAP/VAP according to the 2005 ATS/IDSA guidelines which (2) evaluated the risk factors for DR pathogens and (3) reported the rates of each of the following according to a binary (high/low) risk classification: DR pathogen detection, inadequate empirical treatment, initial nonresponse to treatment, length of intensive care unit (ICU) stay, length of hospital stay, 30-day mortality, and hospital mortality. For any studies that did not classify high- and low-risk by the number of risk factors, we quantify the risk factors and define the high-risk as having >=2 risk factors. In the other systematic review and meta-analysis for comprehensive identification of risk factors for DR pathogens in HAP and VAP, studies meeting both of the following criteria are eligible: (1) prospective studies evaluating the risk factors for DR in HAP and VAP that (2) studies employing a multivariate analysis for identifying risk factors associated with DR pathogens. Studies that performed only univariate analyses are excluded because they usually contain inflated association measures.
Exclusion criteria
Exclusion criteria: Exclusion criteria in the above two systematic reviews and meta-analyses are as follows: (1) studies that included only paediatric populations (<15 years old); (2) studies that included only VAP patients or did not exclude community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) as defined by the 2005 ATS/IDSA guidelines; (3) studies that included only pathogen-specific pneumonia; (4) case reports or reviews; (5) conference presentations; and (6) studies with duplicated eligible patients, such as studies with overlapping periods at the same medical institution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Risk factors for drug-resistant pathogens in HAP/VAP | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment the differences in outcomes between patients with high- and low-risk for drug-resistant pathogens in HAP/VAP | — |
Countries
Japan
Contacts
Public ContactHitoshi Kawasuji
University of Toyama Department of Clinical Infectious Diseases
Outcome results
None listed